295 related articles for article (PubMed ID: 36854989)
1. Prevalence of higher-grade dysplasia in persistently high-risk human papillomavirus positive, cytology negative women after introduction of the new cervical cancer screening in Germany.
Berger L; Wolf-Breitinger M; Weiß C; Tuschy B; Berlit S; Sütterlin M; Spaich S
Cancer Causes Control; 2023 May; 34(5):469-477. PubMed ID: 36854989
[TBL] [Abstract][Full Text] [Related]
2. Risk of cervical high-grade squamous intraepithelial neoplasia in cytologic negative and persistently high-risk human papillomavirus positive patients according to genotypes: a retrospective single center analysis.
Kipp B; Ulrich E; van Meegen C; Schwenzer T
BMC Infect Dis; 2024 Jun; 24(1):558. PubMed ID: 38834951
[TBL] [Abstract][Full Text] [Related]
3. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study.
Tidy JA; Lyon R; Ellis K; Macdonald M; Palmer JE
BJOG; 2020 Sep; 127(10):1260-1267. PubMed ID: 32279427
[TBL] [Abstract][Full Text] [Related]
4. Genotype, cervical intraepithelial neoplasia, and type-specific cervical intraepithelial neoplasia distributions in hrHPV+ cases referred to colposcopy: A multicenter study of Chinese mainland women.
Chen M; Ye Z; Wang H; Cui X; Seery S; Wu A; Xue P; Qiao Y
J Med Virol; 2024 Mar; 96(3):e29475. PubMed ID: 38415472
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of high-grade cervical intraepithelial neoplasia in women with persistent high-risk HPV genotypes and negative cytology.
Macdonald M; Crossley J; Ellis K; Dudding N; Lyon R; Smith JHF; Tidy JA; Palmer JE
Cytopathology; 2018 Apr; 29(2):133-142. PubMed ID: 29350424
[TBL] [Abstract][Full Text] [Related]
6. High-risk HPV testing vs liquid-based cytology for cervical cancer screening among 25- to 30-year-old women: A historical cohort study.
Feldstein O; Gali-Zamir H; Schejter E; Feinberg T; Yehuda-Shnaidman E; Bornstein J; Levy T
Acta Obstet Gynecol Scand; 2023 Feb; 102(2):226-233. PubMed ID: 36478537
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of immediate colposcopy among women with high-risk human papillomavirus (HPV) other than HPV 16/18 and normal cytology.
Aydın S; Öncü HN; Arıcı DS
J Obstet Gynaecol Res; 2021 Feb; 47(2):720-725. PubMed ID: 33314453
[TBL] [Abstract][Full Text] [Related]
8. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population].
Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341
[No Abstract] [Full Text] [Related]
9. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
10. Prospective cohort study examining cervical cancer screening methods in HIV-positive and HIV-negative Cambodian Women: a comparison of human papilloma virus testing, visualization with acetic acid and digital colposcopy.
Thay S; Goldstein A; Goldstein LS; Govind V; Lim K; Seang C
BMJ Open; 2019 Feb; 9(2):e026887. PubMed ID: 30804036
[TBL] [Abstract][Full Text] [Related]
11. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
Tao X; Zhang H; Zhang H; Xiao Y; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
[TBL] [Abstract][Full Text] [Related]
12. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of colposcopy after the addition of human papillomavirus testing to the Turkish cervical cancer screening program.
Gunes AC; Ozgul N; Turkyılmaz M; Kara F; Unlu F; Ayhan A; Gultekin M
Cancer Med; 2023 Dec; 12(24):21751-21760. PubMed ID: 37994572
[TBL] [Abstract][Full Text] [Related]
15. Clinical performance of primary HPV screening cut-off for colposcopy referrals in HPV-vaccinated cohort: Observational study.
Beecroft M; Gurumurthy M; Cruickshank ME
BJOG; 2023 Jan; 130(2):210-213. PubMed ID: 36054732
[TBL] [Abstract][Full Text] [Related]
16. Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program.
Sahlgren H; Elfström KM; Lamin H; Carlsten-Thor A; Eklund C; Dillner J; Elfgren K
Am J Obstet Gynecol; 2020 Mar; 222(3):253.e1-253.e8. PubMed ID: 31585095
[TBL] [Abstract][Full Text] [Related]
17. Subsequent risk and presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer after a colposcopic diagnosis of CIN 1 or less.
Pretorius RG; Peterson P; Azizi F; Burchette RJ
Am J Obstet Gynecol; 2006 Nov; 195(5):1260-5. PubMed ID: 17074547
[TBL] [Abstract][Full Text] [Related]
18. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
[TBL] [Abstract][Full Text] [Related]
19. The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer.
Barrett JE; Sundström K; Jones A; Evans I; Wang J; Herzog C; Dillner J; Widschwendter M
Genome Med; 2022 Oct; 14(1):116. PubMed ID: 36258199
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J
JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
